Roberts, Reade B <br/><br/>
Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies.  [electronic resource] 

 -  Cancer cell  Feb 2004 
 - 115-20 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review 
<br/><br/><label>ISSN: </label>1535-6108 
<br/><br/><label>Standard No.: </label>10.1016/s1535-6108(04)00032-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--adverse effects<br/>Benzamides<br/>Cardiomyoplasty<br/>Colorectal Neoplasms--drug therapy<br/>Cyclooxygenase 2<br/>Disease Models, Animal<br/>ErbB Receptors--antagonists & inhibitors<br/>Gastrointestinal Diseases--chemically induced<br/>Genes, abl--physiology<br/>Genetic Engineering<br/>Humans<br/>Imatinib Mesylate<br/>Isoenzymes--antagonists & inhibitors<br/>Membrane Proteins<br/>Mice<br/>Mice, Transgenic--genetics<br/>Neoplasms--drug therapy<br/>Piperazines--adverse effects<br/>Prostaglandin-Endoperoxide Synthases--metabolism<br/>Pyrimidines--adverse effects<br/>Receptors, Platelet-Derived Growth Factor<br/>Receptors, Transforming Growth Factor beta--antagonists & inhibitors<br/>Skin Abnormalities--chemically induced<br/>Trastuzumab<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors